Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
In a recent transaction, Troy Wichterman, the Chief Financial Officer of BioLife Solutions Inc. (NASDAQ:BLFS), sold a significant portion of the company’s stock. According to a filing with the Securities and Exchange Commission, Wichterman sold 25,687 shares of common stock on April 1, 2025, at a price of $22.66 per share. The total value of the transaction amounted to $582,067. The sale comes as BioLife’s stock has experienced significant volatility, with InvestingPro data showing a 9% decline over the past week, though maintaining a 37% gain over the past year.
Following the sale, Wichterman retains ownership of 189,242 shares in the company. According to InvestingPro analysis, BioLife Solutions maintains strong financial health with a current ratio of 4.54, indicating robust liquidity. The transaction was executed as part of a Rule 10b5-1 trading plan, which was established to address tax withholding obligations related to the vesting of restricted stock. Subscribers to InvestingPro can access 8 additional key insights about BLFS, including detailed financial health metrics and growth projections.
In other recent news, BioLife Solutions has reported its financial results for the fourth quarter and full year of 2024, revealing a total revenue of $22.7 million for the quarter, which surpassed analyst estimates. The company experienced a net loss of $2.0 million, or ($0.04) per share, which was smaller than projected. For the entire year, BioLife Solutions posted total revenue of $82.3 million, excluding $37.7 million from discontinued operations, and a net loss of $11.4 million. The Cell Processing segment showed a 7% sequential increase in revenue for the fourth quarter and a 12% year-over-year growth, marking five consecutive quarters of revenue growth. Analysts from H.C. Wainwright raised the price target for BioLife Solutions to $30.00, maintaining a "Buy" rating, while Benchmark reiterated a Buy rating with the same price target. KeyBanc Capital Markets also maintained an Overweight rating with a $33.00 target, expressing confidence in the company’s Cell Processing business and new product introductions. The company has completed the sale of non-core assets to focus on its primary bio preservation media business, which accounts for approximately 90% of its revenue. Looking forward, BioLife Solutions anticipates 2025 revenue growth between 16% and 20%, with Cell Processing revenue expected to increase by 18-21%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.